Press Releases

News Brief

Asia's First Bioprocessing Research and Training Institute to Open in South Korea

The South Korean government agencies, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare announced plans to foster Asia's bioprocessing professionals. Dr. Tae Han Kim, CEO of Samsung Biologics attended the signing ceremony to support the agreement with aims to further strengthen and expand Korea's bio-industry 

The South Korean government agencies, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare announced plans to foster Asia's bioprocessing professionals. Dr. Tae Han Kim, CEO of Samsung Biologics attended the signing ceremony to support the agreement with aims to further strengthen and expand Korea's bio-industry. 

 

Under the agreement, the two ministries will build Asia's first state-run bioprocessing research and training institute in Korea. In response to a surge in biomedicine manufacturing in Korea, 60 billion won ($51.3 million) is set to be invested by 2025 to provide advanced training for professionals and resolve imbalances in staffing. This investment is expected to effectively establish Korea as a major biocluster in Asia.  

The South Korean government agencies, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare announced plans to foster Asia's bioprocessing professionals. Dr. Tae Han Kim, CEO of Samsung Biologics attended the signing ceremony to support the agreement with aims to further strengthen and expand Korea's bio-industry 

The South Korean government agencies, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare announced plans to foster Asia's bioprocessing professionals. Dr. Tae Han Kim, CEO of Samsung Biologics attended the signing ceremony to support the agreement with aims to further strengthen and expand Korea's bio-industry. 

 

Under the agreement, the two ministries will build Asia's first state-run bioprocessing research and training institute in Korea. In response to a surge in biomedicine manufacturing in Korea, 60 billion won ($51.3 million) is set to be invested by 2025 to provide advanced training for professionals and resolve imbalances in staffing. This investment is expected to effectively establish Korea as a major biocluster in Asia.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION